Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...
The therapy, called photobiomodulation or “red light” therapy, can reduce the risk of vision loss and slow progression of the ...
Preliminary data from a late stage clinical trial of a retinal implant showed promising results, Science Corporation said ...
A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...
The following is a summary of “Submacular hemorrhage rates following anti-vascular endothelial growth factor injections for ...
MedPage Today on MSN2d
Approval of Bevacizumab Biosimilar Could Eliminate Access to Low-Cost AMD TherapyCHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a ...
Roche has released positive topline one-year findings from a Phase IV trial of Vabysmo (faricimab) to treat diabetic macular ...
Investment analysts at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a report released on Friday. The brokerage set a “sell” rating on the ...
Dr Arshad Khanani anticipates presentations offering new strategies to tackle challenges such as macular atrophy and fibrosis, and optimizing dosing intervals in wet AMD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback